Liraglutide n =1363	Exenatide n =231	Placebo n =524
Cardiovascular risk markers, relative change (%)
Brain natriuretic peptide	−11.9*	−3.9	1.4
High-sensitivity C-reactive protein	−23.1†	−15.6*	−3.0
Lipids, change (mg/dL)
Total cholesterol	−2.3*	−0.9	0.2
LDL-cholesterol	−3.6†	−2.7‡	−2.3‡
HDL-cholesterol	−0.7†	−0.9*	−0.5‡
Triglycerides	−3.6*	−0.9	−0.4

*P<0.01 vs. baseline.

†P<0.001 vs. baseline.

‡P<0.05 vs. baseline.

HDL=high-density lipoprotein; LDL=low-density lipoprotein.

Adapted with permission from: Plutzky J, Garber A, Falahati A, Taft AD, Paultzer NR. Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. 20th World Diabetes Congress; October 18–22, 2009; Montreal, Canada. Abstract O-0542. Available at: http://www.diabetes.ca. Accessed August 15, 2009.